Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
bioCSL and PharmaJet announced that the Food and Drug Administration (FDA) has approved the PharmaJet Stratis 0.5mL Needle-Free Jet Injector for delivery of Afluria (trivalent, inactivated “split virus” influenza vaccine) in patients aged 18–64 years.
This is the first needle-free formulation approved for an inactivated influenza vaccine. The FDA approval was based on results from a randomized controlled clinical trial that showed non-inferiority of the immune response to the 3 influenza strains contained in Afluria when administered with the Stratis Injector vs. traditional needle and syringe.
RELATED: CDC Updates Flu Vaccine Recommendations for 2014-15
The PharmaJet injector technology allows vaccine delivery through a narrow, precise fluid stream that penetrates the skin in about one-tenth of a second. The PharmaJet Stratis Needle-Free Injection System consists of a reusable injector that delivers a single-dose with a disposable cartridge. It contains an adapter that can be used with vaccine vials.
For more information call (888) 900-4321 or visit PharmaJet.com.
